0
Center for Cancer Research
Update
Robert H. Wiltrout, Ph.D., Director
Lee A. Helman, M.D., SD for Clinical Research
Decemb...
CCR Is An Integral Part of NCI
National Cancer Institute
Intramural
Divisions
Extramural
Divisions
Center to Reduce Cancer...
CCR Vision
Integrate basic, translational, and
clinical research to make cancer
preventable, curable, or
chronically manag...
CCR Mission:
Focused On The Patient
To inform and empower the entire cancer research
community by making breakthrough disc...
CCR Seeks to Achieve
Its Mission By:
• Performing rigorous basic scientific research to discover fundamental
mechanisms of...
CCR ScientificPresenations to the
148th
Meeting of the NCAB
• Dr. Natasha Caplen - Defining the Cancer Genome
using RNAi A...
Center for Cancer Research
Update – Closed Session
Robert H. Wiltrout, Ph.D.
Director
December 9, 2008
NCAB
Distinctive Qualities of CCR
• Critical mass of basic and clinical scientists solving
complex scientific problems
• Can qu...
Cellular Oncology Populations Genetics
Cell & Cancer Biology Immune Cell Biology
Resistance Mechanisms Macromolecular Crys...
Dermatology Genetics
Medical Oncology Neuro-Oncology
Urologic Oncology Pediatric Oncology
Experimental Transplant. Immunol...
CCR Labs and Branches Are Woven
Together Around Strategic Priorities
• Understand the Cancer Process from Initiation to
Me...
Centers of Excellence serve as Focal
Points for Bench to Bedside Translation
• Centers of Excellence serve to support the
...
Strategies for Programmatic
Integration
Translational Infrastructure Is Collaborative
Research Emphasis Today
Commercial Successes in Fighting
Cancer and HIV
Vaccines and Therapeutics
2-F-AraA - Fludara (April 18, 1991) Berlex
Videx...
Jairaj Acharya, MBBS, Ph.D.
Laboratory of Cell and
Developmental Signaling
Newly Tenured
Phospholipid and sphingolipid sig...
Javed Khan, M.D.
Pediatric Oncology Branch
Newly Tenured
Applying high throughput genomics and proteomics to
characterize ...
0
20
40
60
80
%ofInvestigators
FY04
N=56
Expansions Continuations
Reductions
Closures
Re-reviews
SV & BSC Recommendations
...
FY08 Reallocations of Recovered Funds
Basic 45%
Translational
27%
Clinical
24%
Meetings, Retreats 5%
2.8 Million
220
230
240
250
260
270
280
290
300
310
320
2002 2003 2004 2005 2006 2007 2008 2009
Number of CCR PIs: 2000-2009
* project...
Rebuilding the Principal Investigator
Community – FY2008
Senior Leadership
• Crystal Mackall, Chief, POB
• J. Carl Oberhol...
Open PI Positions (Nov 2008)
• Mouse Cancer Genetics Program: 2 Tenure Track or Tenured
Positions
• Laboratory of Human Ca...
Major Searches (Nov 2008)
• Stem Cell Program
- 29 applications received
- 15 top candidates reviewed by
Search Committee
...
Center for Cancer Research
Update – Closed Session
Robert H. Wiltrout, Ph.D.
Director
December 9, 2008
NCAB
The NCI Intramural
Clinical Research Program
• The NCI intramural clinical program is not a large volume,
full-service can...
Upcoming SlideShare
Loading in...5
×

Introduction

650

Published on

Published in: Technology, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
650
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • Basic research is a strength of the CCR, with areas of investigation including: immunology, carcinogenesis, human genetics, mouse genetics, viral oncology, HIV, chromatin biology, structural biology, DNA replication and recombination, signal transduction, apoptosis, cell cycle regulation, cytokines and chemokines, cellular, molecular and developmental biology, medicinal chemistry and natural products chemistry, molecular pharmacology, xenobiotic metabolism, radiation biology, computational biology and bioinformatics.
    Areas of excellence in clinical and translational research include: cancer vaccines, clinical proteomics, molecular targets of cancer, molecular imaging, biologic mediators, cell-based therapies, immunotoxin therapy, radiation therapy, cancer genetics, molecular epidemiology, cancer prevention, multidrug resistance, clinical pharmacology, angiogenesis and molecular pathology.
    Programs encompass investigators, organized within a specific field of research, who are working together to solve a complex scientific problem.
    AIDS Vaccine Program – Larry Arthur, Ph.D
    Computational Applications Program – Stan Burt, Ph.D
    HIV Drug Resistance Program – John Coffin, Ph.D.
    Molecular Targets Drug Discovery Program
    Mouse Cancer Genetics Program – Neal Copeland, Ph.D.
    Radiation Oncology Sciences Program (ROSP) – C. Norman Coleman, M.D.
  • Basic research is a strength of the CCR, with areas of investigation including: immunology, carcinogenesis, human genetics, mouse genetics, viral oncology, HIV, chromatin biology, structural biology, DNA replication and recombination, signal transduction, apoptosis, cell cycle regulation, cytokines and chemokines, cellular, molecular and developmental biology, medicinal chemistry and natural products chemistry, molecular pharmacology, xenobiotic metabolism, radiation biology, computational biology and bioinformatics.
    Areas of excellence in clinical and translational research include: cancer vaccines, clinical proteomics, molecular targets of cancer, molecular imaging, biologic mediators, cell-based therapies, immunotoxin therapy, radiation therapy, cancer genetics, molecular epidemiology, cancer prevention, multidrug resistance, clinical pharmacology, angiogenesis and molecular pathology.
    Programs encompass investigators, organized within a specific field of research, who are working together to solve a complex scientific problem.
    AIDS Vaccine Program – Larry Arthur, Ph.D
    Computational Applications Program – Stan Burt, Ph.D
    HIV Drug Resistance Program – John Coffin, Ph.D.
    Molecular Targets Drug Discovery Program
    Mouse Cancer Genetics Program – Neal Copeland, Ph.D.
    Radiation Oncology Sciences Program (ROSP) – C. Norman Coleman, M.D.
  • 2 retirees were added for FY08
    David Nelson
    John Weinstein
  • As in the past % allocation is based on the RRS request system. 12.6 milion was distributed via RRS in FY08; 1.2 million was recouped from the site visit process + an additional 1.595 mil was recovered due to the retirements of John Weinstein, David Nelson and Wayne Anderson.
  • Hope to get to 280-290 and maintain a steady state there. That is if closures/retirements in a year, we should be replacing those positions.
  • Transcript of "Introduction"

    1. 1. Center for Cancer Research Update Robert H. Wiltrout, Ph.D., Director Lee A. Helman, M.D., SD for Clinical Research December 9, 2008 NCAB
    2. 2. CCR Is An Integral Part of NCI National Cancer Institute Intramural Divisions Extramural Divisions Center to Reduce Cancer Health Disparities Division of Cancer Treatment and Diagnosis Office of Centers, Training, and Resources Division of Cancer Control and Population Sciences Division of Cancer Epidemiology and Genetics Division of Cancer Biology Division of Cancer Prevention
    3. 3. CCR Vision Integrate basic, translational, and clinical research to make cancer preventable, curable, or chronically manageable.
    4. 4. CCR Mission: Focused On The Patient To inform and empower the entire cancer research community by making breakthrough discoveries in basic and clinical cancer research and by developing them into novel therapeutic interventions for adults and children afflicted with cancer or infected with HIV.
    5. 5. CCR Seeks to Achieve Its Mission By: • Performing rigorous basic scientific research to discover fundamental mechanisms of biology and cancer • Translating these advances rapidly from the laboratory to the clinic • Developing innovative technologies that enable more accurate detection, diagnoses, and treatments • Pioneering novel interventions for underserved patient populations • Sharing expertise, scientific data and technologies to broaden the impact of our work and enhance the overall productivity of the cancer research community • Providing a unique environment to cultivate and train future physician- scientists and biomedical researchers
    6. 6. CCR ScientificPresenations to the 148th Meeting of the NCAB • Dr. Natasha Caplen - Defining the Cancer Genome using RNAi Analysis and Screening • Dr. Stephan Ambs - Application of Genomic Profiling to Identify Factors that contribute to Cancer Health Disparities • Dr. Terry Van Dyke - Cancer Models: From Insight to Improved Care • Dr. Marston Linehan – The Genetic Basis of Kidney Cancer: Opportunity for Targeted Approaches to Therapy
    7. 7. Center for Cancer Research Update – Closed Session Robert H. Wiltrout, Ph.D. Director December 9, 2008 NCAB
    8. 8. Distinctive Qualities of CCR • Critical mass of basic and clinical scientists solving complex scientific problems • Can quickly redeploy resources to address: • (a) NCI mission goals-reduce the burden of cancer • (b) Urgent public need-response to AIDS epidemic • (c) New opportunities-decoding of the human genome • Access to NIH Clinical Center
    9. 9. Cellular Oncology Populations Genetics Cell & Cancer Biology Immune Cell Biology Resistance Mechanisms Macromolecular Crystallography Molecular Pharmacology Cancer & Inflammation Cancer Biology and Genetics Cell & Developmental Signaling Cancer Prevention Nanobiology Genomic Diversity Basic Research Cell Biology Molecular Biology Molecular Pharmacology Structural Biophysics Medicinal Chemistry Protein Dynamics & Signaling Molecular Targets Discovery Experimental Immunology Molecular Cell Biology Comparative Carcinogenesis Cell Regulation & Carcinogenesis Molecular Immunoregulation Experimental Carcinogenesis Cancer & Development Biology Human Carcinogenesis Mouse Cancer Genetics Retroviral Replication HIV Drug Resistance Mammary Biology & Tumorigenesis Receptor Biology and Gene Expression HIV Drug Resistance Cellular Carcinogen & Tumor Prom Gene Regulation & Chromosome Biology Cellular & Molecular Biology Biochemistry & Molecular Biology Center for Cancer Research: Organization Center for Cancer Research Clinical Branches Basic Laboratories
    10. 10. Dermatology Genetics Medical Oncology Neuro-Oncology Urologic Oncology Pediatric Oncology Experimental Transplant. Immunol. Surgery Experimental Immunology Radiation Oncology Tumor Immunol. & Biology Radiation Biology HIV & AIDS Malignancy Pathology Metabolism Molecular Imaging Biostatistics & Data Mgmt Vaccine Center for Cancer Research: Organization Center for Cancer Research Clinical Branches Basic Laboratories
    11. 11. CCR Labs and Branches Are Woven Together Around Strategic Priorities • Understand the Cancer Process from Initiation to Metastasis • Interrogate the Molecular Genetics of Cancer • Improve Cancer Prevention, Early Detection, and Diagnostic Approaches • Develop and Validate Novel Molecularly Targeted Interventions • Harness the Immune System to Combat Cancer • Discover and Develop Approaches to Combat HIV/AIDS and AIDS-associated Malignancies
    12. 12. Centers of Excellence serve as Focal Points for Bench to Bedside Translation • Centers of Excellence serve to support the IRPs dedication to long-term, high-risk, innovative basic, clinical, and epidemiologic research • Immunology - Robert Wiltrout, Head • Chromosome Biology – Gordon Hager, Head • HIV/AIDS and Cancer Virology - Stuart LeGrice, Head • Molecular Oncology - Giuseppe Giaccone, Pat Steeg, Head • Integrative Biology, Snorri Thorgeirsson, Head Program/Initiative • Cancer and Inflammation – Giorgio Trinchieri, Head
    13. 13. Strategies for Programmatic Integration Translational Infrastructure Is Collaborative
    14. 14. Research Emphasis Today
    15. 15. Commercial Successes in Fighting Cancer and HIV Vaccines and Therapeutics 2-F-AraA - Fludara (April 18, 1991) Berlex Videx (October 9, 1991) Berlex Lab Hivid (June 19, 1992) BMS Paclitaxel (Dec. 29, 1992) BMS Trimetrexate – Neu Trexin (Dec. 17, 1993) Zenapax (Dec. 10, 1997) Hoffman La Roche Vitravene (Aug. 26, 1998) Isis Pharma Kepivance (Dec. 15, 2004) Amgen Zevalin (Feb. 19, 2002) IDEC Pharma Gardasil (June 8, 2006) Merck Prezista (June 23, 2006) Tibotec Pharma Diagnostics Serological Detection of Antibodies to HIV-1 (March 1, 1985) Serologic Detection of Antibodies to HTLV-1 (Nov. 29, 1988) DNA Probe for Breast Cancer Diagnosis (Dec. 11, 1998) Multi-replica Blotting Kit for Proteins Instrumentation/Devices Laser Capture Microdissection
    16. 16. Jairaj Acharya, MBBS, Ph.D. Laboratory of Cell and Developmental Signaling Newly Tenured Phospholipid and sphingolipid signaling in Drosophila
    17. 17. Javed Khan, M.D. Pediatric Oncology Branch Newly Tenured Applying high throughput genomics and proteomics to characterize high risk pediatric malignancies, focusing on neuroblastoma.
    18. 18. 0 20 40 60 80 %ofInvestigators FY04 N=56 Expansions Continuations Reductions Closures Re-reviews SV & BSC Recommendations N= 10 42 37 5 9 10 58 21 FY05 N=89 FY06 N=76 9 54 13 4 38 16 FY07 N=58 Retirements 12 FY08 N=56
    19. 19. FY08 Reallocations of Recovered Funds Basic 45% Translational 27% Clinical 24% Meetings, Retreats 5% 2.8 Million
    20. 20. 220 230 240 250 260 270 280 290 300 310 320 2002 2003 2004 2005 2006 2007 2008 2009 Number of CCR PIs: 2000-2009 * projected Projected 12 additional PIs in FY09 Slide 19
    21. 21. Rebuilding the Principal Investigator Community – FY2008 Senior Leadership • Crystal Mackall, Chief, POB • J. Carl Oberholtzer, Chief, LP • Kevin Camphausen, Chief, ROB • R. Andrew Byrd, Acting Director, Molecular Discovery Program • Robert Yarchoan, Director for the NCI Office of HIV and AIDS Malignancies • L. Michelle Bennett, Deputy Director CCR Newly Hired Tenure Tracks • Itzhak Avital, SB • Peter Kalab, LCMB • Udai Kammula, SB • Yamini Dalal, LRBGE • Yinling Hu, LEI • Jing Huang, LCBG • Jung-Hyun Park, EIB • Li Yang, LCBG • Joseph Ziegelbauer, HAMB • Ola Landgren, MOB • Mitchell Ho, LMB • Brian Lewis, MB • Chris Buck, LOC • Deb Citrin, ROB • King Kwong, SB
    22. 22. Open PI Positions (Nov 2008) • Mouse Cancer Genetics Program: 2 Tenure Track or Tenured Positions • Laboratory of Human Carcinogenesis: Tenure Track • Metabolism Branch: 2 Tenure Track positions • Medical Oncology Branch: Tenure Track in breast cancer • Laboratory of Biochemistry and Molecular Biology: Tenure Track • Laboratory of Molecular Biology: Tenure Track • Chronic Inflammation & Cancer: Tenure Track • Neuro Oncology Branch: Tenure Track
    23. 23. Major Searches (Nov 2008) • Stem Cell Program - 29 applications received - 15 top candidates reviewed by Search Committee - 6 top candidates interviewed • Chemical Biology Laboratory Ad has been posted Overwhelmingly positive response from 24 well-qualified applicants, interviews are scheduled with 8 top candidates
    24. 24. Center for Cancer Research Update – Closed Session Robert H. Wiltrout, Ph.D. Director December 9, 2008 NCAB
    25. 25. The NCI Intramural Clinical Research Program • The NCI intramural clinical program is not a large volume, full-service cancer center • The NCI intramural clinical program is the largest cancer- focused clinical research center (CRC) in the world, capable of performing patient-intensive clinical research focused on developing new approaches for prevention, diagnosis, and treatment of cancer. • The NCI intramural clinical program is an important component of the nation’s overall cancer program
    1. A particular slide catching your eye?

      Clipping is a handy way to collect important slides you want to go back to later.

    ×